What is the appropriate treatment approach for amenorrhea?

Treatment of Amenorrhea

Treatment of amenorrhea must be directed by the underlying cause, with the primary goals of preventing complications (osteoporosis, endometrial hyperplasia, cardiovascular disease), preserving fertility when desired, and ensuring normal pubertal development in primary amenorrhea. 1, 2

Initial Diagnostic Framework

Before initiating treatment, establish whether amenorrhea is primary (no menarche by age 15 or 3 years post-thelarche) or secondary (cessation of regular menses for 3 months or irregular menses for 6 months). 3, 4

All patients require:

• Pregnancy test (mandatory first step) 3, 4
• Serum FSH, LH, prolactin, and TSH levels 1, 3
• Assessment of pubertal development, BMI, and presence of hyperandrogenic signs 3

Treatment Based on Underlying Cause

PCOS-Related Amenorrhea (Most Common Cause of Secondary Amenorrhea)

For women NOT seeking pregnancy:

• Combined oral contraceptives are first-line treatment, regulating cycles, providing endometrial protection against unopposed estrogen, and reducing androgen levels 1, 2, 5
• If COCs are contraindicated, use cyclic progestin therapy (medroxyprogesterone acetate) to prevent endometrial hyperplasia 1, 2
• Lifestyle modification targeting 5-10% weight loss through 500-750 kcal/day energy deficit is mandatory for ALL women with PCOS regardless of BMI, as metabolic benefits occur even in normal-weight patients 5
• Add metformin 500-2000 mg daily when insulin resistance or glucose intolerance is documented, or when lifestyle modifications alone are insufficient 5
• For persistent hirsutism/acne after 3-6 months of optimal-dose COC therapy, add spironolactone 50-100 mg daily (never without effective contraception due to teratogenic risk) 5

For women seeking pregnancy:

• Structured lifestyle modification remains mandatory first-line treatment 5
• Clomiphene citrate is first-line pharmacological treatment, inducing ovulation in ~80% with ~50% conception rate among ovulators 1, 5
• Low-dose gonadotropin therapy if clomiphene fails 5

Critical metabolic screening:

• Screen ALL PCOS patients for type 2 diabetes and dyslipidemia regardless of weight 2, 5
• Calculate BMI and waist-hip ratio using ethnic-specific cutoffs 5
• Repeat screening at least annually 5

Functional Hypothalamic Amenorrhea (FHA)

Distinguish from PCOS: FHA presents with low estrogen and true amenorrhea, whereas PCOS has normal/elevated estrogen with breakthrough bleeding 2

Treatment hierarchy:

1. Address underlying causes: Reduce excessive exercise, correct energy deficits (target energy availability ≥30 kcal/kg FFM/day), manage psychological stress, and aim for BMI ≥18.5 kg/m² 1, 6
2. Increase body fat percentage above 22% may be required to restore menstruation; even 1 kg increase in fat mass raises menstruation likelihood by 8% 6
3. For women NOT seeking pregnancy: Hormone replacement therapy to prevent hypoestrogenic complications (osteoporosis, cardiovascular disease) 1
4. For women seeking pregnancy: Pulsatile GnRH therapy is more effective than exogenous gonadotropins 1

Pitfall to avoid: Screen for eating disorders and low bone density, as these are common comorbidities 1, 3

Hyperprolactinemia

• Prolactin-lowering drugs (dopamine agonists) are primary treatment 7
• Cyclic progestogen or HRT for cycle regulation in those not seeking pregnancy 7
• Oral contraceptives if contraception is needed 7

Primary Ovarian Insufficiency (Hypergonadotropic Amenorrhea)

• No curative therapy exists 7
• Hormone replacement therapy is mandatory to prevent cardiovascular disease and osteoporosis from long-term hypoestrogenism 1, 7
• Patients can maintain unpredictable ovarian function and should not be presumed infertile; contraception may still be needed 3, 4

Thyroid Dysfunction

• Appropriate thyroid hormone replacement or suppression as indicated 1

Anatomic Outflow Tract Abnormalities

• Surgical correction for imperforate hymen, transverse vaginal septum, or other structural abnormalities 8
• Müllerian agenesis requires karyotype confirmation (46,XX) and individualized management 8

Universal Endometrial Protection Principle

Women with chronic anovulation and amenorrhea are at significantly increased risk for endometrial hyperplasia and cancer due to unopposed estrogen exposure. 1, 2

• Amenorrhea >3 months triggers need for endometrial protection 2
• Use either combined hormonal contraception OR cyclic progestin therapy 1, 2

Common Pitfalls to Avoid

• Never fail to distinguish between PCOS and FHA, as management differs fundamentally despite possible overlapping ultrasound findings 1, 2
• Never prescribe spironolactone without confirmed effective contraception due to teratogenic risk 5
• Never omit metabolic screening in normal-weight PCOS patients, as metabolic abnormalities occur regardless of BMI 5
• Never overlook endometrial protection in women with prolonged amenorrhea from any cause 2
• Never assume infertility in primary ovarian insufficiency, as ovarian function remains unpredictable 3, 4